Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
|Articles|July 17, 2017
Supplements and Featured Publications
- Rheumatoid Arthritis:The Next Generation of Treatment
- Volume 22
- Issue 14
Rheumatoid Arthritis: The Next Generation of Treatment Post Test
Advertisement
Release date: September 12, 2016
Expiration date: September 12, 2017
Pharmacy Credit
Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information
This lesson is free online; receive instant grading and request your CE credit at www.PharmacyTimes.org.
Testing and Grading Directions
Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest is eligible to receive CE credit.
Articles in this issue
over 9 years ago
Participating Facultyover 9 years ago
Rheumatoid Arthritis: Many Management Strategies, No CureAdvertisement
Related to this article
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
3
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
4
Oral Iberdomide May Widen Myeloma Access: Mateo Mejia Saldarriaga, MD
5